Korro Bio (KRRO) EPS (Basic) Growth (3y) (2021 - 2026)
Powered by 
Analysis
Korro Bio (KRRO) EPS (Basic) Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | - |
| 10 | Korro Bio | 227.98 Mn | 112.95 Mn | - | 74.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 74.38% |
| Mar 31, 2026 | 71.38% |
| Dec 31, 2025 | -28.35% |
| Sep 30, 2025 | 58.91% |
| Jun 30, 2025 | 55.15% |
| Mar 31, 2025 | 57.98% |
| Dec 31, 2024 | 76.56% |
| Sep 30, 2024 | 60.46% |
| Jun 30, 2024 | 54.50% |
| Mar 31, 2024 | 56.61% |
| Dec 31, 2023 | -1.58% |
| Sep 30, 2023 | -45.83% |
| Jun 30, 2023 | -87.42% |
| Mar 31, 2023 | -108.57% |
| Dec 31, 2022 | 40.24% |
| Sep 30, 2022 | 8.94% |
| Jun 30, 2022 | 43.74% |
| Mar 31, 2022 | 40.81% |
| Dec 31, 2021 | 43.98% |
| Sep 30, 2021 | 39.27% |